Estimate risk-adjusted net present value for a pharmaceutical or biotechnology development program at each clinical stage. Enter your program assumptions to generate rNPV estimates and a sensitivity analysis.
Enter the development parameters and commercial assumptions for your program below. Default success probabilities reflect published industry-wide averages. Adjust all inputs to reflect program-specific expectations and click Calculate to generate results.
Phase 1 rNPV
—
Enter assumptions & calculate
Phase 2 rNPV
—
Phase 3 rNPV
—
Approval rNPV
—
rNPV Progression by Stage
Sensitivity Analysis — Impact on Phase 1 rNPV
| Parameter | Value |
|---|
The Risk-Adjusted Net Present Value (rNPV) method is the standard framework for valuing pharmaceutical and biotechnology development programs. It explicitly accounts for the risk of clinical failure at each stage rather than adding an arbitrary risk premium to the discount rate — an approach widely regarded as both conceptually incorrect and practically misleading.
The model begins at regulatory approval and works backwards through each clinical stage. At approval, the commercial net present value is computed as the sum of discounted annual free cash flows over the effective patent treatment period, assuming a linear revenue ramp to peak sales. This commercial NPV is then risk-adjusted backwards through each stage by multiplying by the stage-specific probability of technical success p(TS) and discounting by the stage duration, net of stage costs.
Each stage card reports the cumulative probability of reaching regulatory approval from that point forward — the product of all remaining p(TS) values. Using published industry averages (Phase I = 52%, Phase II = 29%, Phase III = 58%, FDA Approval = 90%), the compound probability from Phase I to approval is approximately 7.9%. Program-specific rates may differ materially based on mechanism of action, indication, and available clinical data.
The model applies a single discount rate across all stages. In practice, the appropriate rate for a pharmaceutical development program is typically an industry-level cost of capital reflecting systematic risk only — not a company-specific rate incorporating idiosyncratic risk, which is already captured in the p(TS) probabilities.
For a formal valuation engagement, Windeye Partners typically applies rNPV in conjunction with Monte Carlo simulation and, where appropriate, Real Options analysis, to provide a fuller picture of the distribution of outcomes. Please see our Biotechnology & Pharma Valuations page for more detail.
Important Disclaimer
This calculator is provided by Windeye Partners for informational and illustrative purposes only. Results are highly sensitive to input assumptions and should not be relied upon as a basis for investment, transactional, or strategic decisions without independent professional analysis. The rNPV methodology involves inherent uncertainty; actual program values may differ materially from modeled outputs. This tool does not constitute a valuation opinion, financial advice, or a solicitation or offer to buy or sell any security or financial instrument. Past performance is no guarantee of future results. Windeye Partners accepts no liability for decisions made in reliance on this calculator. For a formal valuation of a pharmaceutical or biotechnology asset, please contact us.
Contact Windeye Partners to discuss how we can assist with a rigorous rNPV, Monte Carlo, or Real Options analysis for your program.